EDARBYCLOR (Azilsartan Kamedoxomil; Chlorthalidone) Patent Expiration, LOE Window & CMS Spending
EDARBYCLOR (Azilsartan Kamedoxomil; Chlorthalidone) by Azurity: FDA Orange Book core substance LOE 2030-02-04 (last listed 2031-07-01), 1 AB generics, $0 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Azurity |
| FDA Application & Pathway | N202331 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-02-04 |
| Last Listed Patent or Exclusivity Date | 2031-07-01 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 24.3% 2-yr change) |